首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1140675

2022-2029 年全球猪瘟 (CSF) 疫苗市场

Global Classical Swine Fever Vaccines Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

在预测期内，新动物疫苗的推出将继续支持市场增长。

兽用疫苗可改善伴侣动物的健康，防止家畜和野生动物在动物之间传播疾病和传染病。因此，动物保健公司正在开发新的动物疫苗。市场增长的主要驱动力之一是动物疫苗製造商推出的新动物疫苗的数量。2020 年 5 月，Indian Immunologicals Limited（IIL）推出了品牌名称为“Raksha Class”的经典猪瘟 (CSF) 疫苗。该疫苗是与Bareilly的印度兽医研究所 (IVRI) 合作开发的。

此外，猪瘟的不断研发正在推动全球猪瘟市场的增长。猪瘟又称猪瘟，是一种猪的传染性病毒性疾病，包括野猪。属于黄病毒科瘟病毒属的结合病毒，与牛病毒性腹泻和临界疾病密切相关。它导致包括印度在内的几个国家的猪死亡率很高。印度自 1964 年以来一直在使用英国开发的猪瘟 (CSF) 疫苗，但由于印度饲养的猪数量不断增加，因此鼓励开发本地生产的猪瘟 (CSF) 疫苗。我们是。

此外，养猪者对疫苗接种意识的提高正在推动全球市场的增长。接种疫苗是控制猪群疾病的必要措施。猪疫苗旨在减少易感动物的数量、临床疾病和病原体的传播。猪疫苗可以保护猪免受传染病的侵害，其中主动和被动免疫是保护自己免受疾病侵害的方法。根据猪健康信息中心 (SWIC) 的说法，猪特斯科病毒 (PTV) 是小核糖核酸病毒科特斯科病毒属的一种无包膜 RNA 病毒。已知大约有 13 种 PTV 血清型，其中 PTV-1 与 Tescovirus 脑脊髓炎有关。PTV-2、PTV-3 和 PTV-5 与塔凡病有关。猪的 PTV 感染可能是亚临床的。

然而，严格的监管政策正在抑制全球猪瘟（CSF）疫苗市场的增长。批准和许可动物疫苗接种需要各种法规和政策。每个国家都有监管机构制定动物疫苗接种的标准和协议。例如，美国农业部下属的动植物卫生检验局 (APHIS) 的兽医生物製品中心 (CVB) 负责监管美国疫苗的生产和销售。兽药公司必须获得 CVB 法规授予的产品许可证和设施许可证。这些许可证是在经过检查的设施和适当的条件下授予的。CVB 要求所有产品都经过批准程序，以确保它们符合 1913 年病毒血清毒素法案中规定的四个特征（纯度、效力、安全性和有效性）。

地理渗透：

北美是预测期内的主要地区。

北美在全球猪瘟 (CSF) 疫苗市场上占据主导地位，预计在预测期内将保持其地位。在预测期内，美国在北美猪瘟 (CSF) 疫苗市场的市场份额最高。发达的医疗基础设施和用于开发针对各种疾病的新型疫苗的巨额研发支出是支持该地区猪瘟 (CSF) 疫苗市场增长的因素之一。

欧洲在全球猪瘟（CSF）疫苗市场上占据第二主导地位。猪肉的高消费是推动该地区市场增长的主要因素之一。西班牙在欧洲猪肉产业中占有重要份额。由于养猪场众多，猪肉生产主要集中在该国西部地区。猪肉行业边际聚落的扩大也是导致猪肉养殖市场集中的主要因素之一。西班牙占欧洲生猪的 24%。

据估计，在预测期内，亚太地区的猪瘟 (CSF) 疫苗市场将以显着的增长率增长。这种增长归因于有效疫苗的研究和开发的增加。例如，2020 年 2 月，印度科学家在印度研製出一种新的疫苗来控制经典猪瘟。该疫苗将有助于生产一种有效的石膏替代品，以替代目前使用的疫苗，以预防占该国肉类总产量 10% 的猪致命发烧。

竞争格局：

猪瘟（CSF）疫苗市场是一个竞争激烈的市场。对全球市场增长做出贡献的主要猪瘟（CSF）疫苗公司是Panav Biotech、Boehringer Ingelheim International GmbH、Ceva、Bioveta、a.s.、Indian Immunologicals Limited、Qilu Animal Health Products Co, Ltd.。主要参与者正在为猪瘟 (CSF) 疫苗市场的全球增长采用新产品发布和扩张战略。几家主要参与者已在市场上推出新产品以扩大其产品组合。2020年6月，勃林格殷格翰推出中国自主研发的猪瘟（CSF）疫苗，并获得中国农业农村部颁发的《新兽药註册证》。据说这是首个跨国公司与中国科研院所联合研製的猪瘟活疫苗。一些主要参与者正在遵循併购策略来扩展业务。例如，2021 年 12 月，勃林格殷格翰将收购 Labor Dr. Merk & Kollegen，以加强其下一代免疫肿瘤学项目。此次收购扩大并加速了基于 ATMP 的免疫肿瘤药物开发的综合计划，包括具有修饰糖蛋白 (GP) 平台的水泡性口炎病毒 (VSV) 和癌症疫苗平台。

COVID-19 的影响对全球经典猪瘟 (CSF) 疫苗市场产生了负面影响。

COVID-19 的爆发无疑影响了全球猪瘟 (CSF) 疫苗市场。因为封锁迫使全球猪瘟（CSF）疫苗供应。研究人员将重点转移到开发 COVID-19 疫苗上，这阻碍了猪瘟 (CSF) 疫苗的研发。因此，预计 2020 年猪瘟（CSF）疫苗市场将出现大幅下滑。

Market Overview

Classical Swine Fever Vaccines Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.5 % during the forecast period (2022-2029).

Classical swine fever is a contagious and economically significant viral disease of pigs. The severity of the illness varies with the strain of the virus, the pig's age, and the herd's immune status. Classical swine fever is related to the virus of bovine virus diarrhea (BVD) and sheep's border disease (BD). Suvaxyn CSF Marker is a veterinary vaccine that protects pigs against outbreaks of classical swine fever. It also protects breeding sows to reduce infection of their unborn piglets by classical swine fever virus. This vaccine contains live bovine viral diarrhea virus (BVDV), which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of CSFV. The rising prevalence of awareness regarding the classical swine fever vaccines and the increasing consumption of pork meat are some factors that are expected to propel market growth. Moreover, the introduction of new veterinary vaccines by animal health companies is further supporting the growth of the market across the globe.

Market Dynamics: The introduction of a new veterinary vaccine will continue supporting the market's growth during the forecast period.

Veterinary vaccines improve companion animals' health and prevent animal-to-human transmission of diseases and infections from domestic animals and wildlife. It has led to the development of new veterinary vaccines by animal health companies. One of the major factors augmenting the market's growth includes the number of new veterinary vaccines introduced by veterinary vaccine manufacturers. In May 2020, Indian Immunologicals Limited (IIL) launched the Classical Swine Fever (CSF) vaccine under the brand name 'Raksha Class .'This vaccine was developed in collaboration with the Indian Veterinary Research Institute (IVRI), Bareilly.

Also, Continuous R&D in the field of swine fever is driving the growth of the global classical swine fever market. Classical swine fever (CSF), also termed hog cholera, is an infectious viral disease of pigs, including wild boar. The connective virus is a member of the Flaviviridae's genus Pestivirus family and is intimately connected to bovine viral diarrhea and border disease. It leads to the high fatality of pigs across several countries, including India. The country has been using the UK-developed classical swine fever vaccine since 1964; however, the country is developing a locally manufactured classical swine fever vaccine for the increasing pig population in India.

Moreover, increasing awareness of the vaccination of swineherds is driving the growth of the global market. Vaccination is a necessary tool for controlling diseases in swine herds. The swine vaccine is designed to reduce the number of susceptible animals, clinical diseases, and pathogen spread. The swine vaccine prevents swine from contagious diseases, in which active and passive immunity are methods to protect against disease. According to the Swine Health Information Center (SWIC), Porcine teschovirus (PTV) is a non-enveloped RNA virus in the genusTeschovirus and the family Picornaviridae. There are about 13 known PTV serotypes in which the PTV-1 is linked with teschovirus encephalomyelitis. PTV-2, PTV -3, and PTV -5 are linked with Talfan disease. The PTV infection in swine may be subclinical.

However, stringent regulatory policies are restraining the growth of the global classical swine fever vaccine market. Various regulations and policies are required to approve and authorize animal vaccination. Each country has its regulatory organizations that set the standards and protocols for animal vaccination. For instance, the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS), a USDA branch, regulates vaccine production and marketing in the US. The animal health companies must have both a product license and an establishment license granted by the CVB rules. These licenses are given under some conditions such as inspected facilities and appropriate. The CVB requires all products to undergo an approval process to ensure compliance with the four characteristics outlined in the Virus-Serum-Toxin Act of 1913, including purity, potency, safety, and efficacy.

Market Segmentation: Government tender segment accounted for the highest share in global classical swine fever vaccines market.

The government tender segment held a major share in the classical swine fever vaccines market in the forecast year. The government has a huge focus on containing the spread of classical swine fever, owing to which the government tender is scheduled for the sales of the classical swine fever vaccine. Moreover, the more effective vaccine in government organizations or private organizations under the government's supervision is further expected to contribute to the segment's growth during the forecast period.

The classical swine fever vaccine market has been classified into tissue culture origin and cell line origin based on the type. The tissue culture origin segment accounted for a significant market share in the global classical swine fever vaccine market. Tissue culture origin dominated the classical swine fever vaccines market in the forecast period. Cell culture is widely used in the US biopharmaceutical industries for vaccine production, drug development, and tissue culture. Tissue culture has a huge significance in the classical swine fever vaccine; therefore, considerable growth can be projected in the segment during the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

North America dominated the global classical swine fever vaccines market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American classical swine fever vaccines market in the forecast period. The well-developed healthcare infrastructure and the huge spending on R&D for the development of novel vaccines for a range of diseases are some factors supporting the growth of the classical swine fever vaccines market in the region.

Europe holds a second dominant position in the global classical swine fever vaccines market. The high consumption of pork meat is one of the major factors that drive the market growth in the region. Spain comprises a significant share of the pork industry in Europe. Pork production is mainly accounted for in western parts of the country due to substantial pork breeding farms. Growing marginalization in the pork industry is also one of the major factors contributing to pork husbandry's concentrated market. Spain accounted for 24% of Europe's pigs.

The Asia Pacific is estimated to grow at a considerable growth rate in the classical swine fever vaccines market during the forecast period. This growth can be accredited to the rising R&D for an effective vaccine. For instance, in February 2020, Indian Scientists developed a new vaccine in India to control classical swine fever. This vaccine helps in producing an effective cast alternative to currently used vaccines for preventing the deadly fever in pigs that contribute to 10 % of the country's total meat production.

Competitive Landscape:

The classical swine fever vaccine market is highly competitive. The key classical swine fever vaccine players contributing to the global market's growth include Panav Biotech, Boehringer Ingelheim International GmbH, Ceva, Bioveta, a.s., Indian Immunologicals Limited, and Qilu Animal Health Products Co., Ltd. among others. The major players are adopting new product launches and expansion strategies for global growth in the classical swine fever vaccines market. Some key players launched a new product in the market to expand their product portfolio. In June 2020, Boehringer Ingelheim announced the China-developed classical swine fever vaccine and obtained a "New veterinary drug registration certificate" from the Ministry of Agriculture and Rural Affairs of China. It is regarded as the first classical swine fever live vaccine jointly developed by a multinational company and Chinese research institutes. Some key players follow merger and acquisition strategies to expand their business. For instance, in December 2021, Boehringer Ingelheim to Acquired Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program. This acquisition helped to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies, including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccine platforms.

COVID-19 Impact: Negative impact on the global classical swine fever vaccines market.

The outbreak of COVID-19 has certainly impacted the global classical swine fever vaccines market, as the lockdown has compelled the supply of classical swine fever vaccines across the globe. The researchers' shift in focus toward developing the COVID-19 vaccine has hampered the R&D in the classical swine fever vaccines. Therefore, the classical swine fever vaccine market is expected to foresee a considerable decline in 2020.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Application
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising awareness about CSF in pig farmers
  - 4.1.1.2. Increasing demand for pork meat
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of medical freezers to store vaccine
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
- 7.3.1. Tissue Culture Origin*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Cell Line Origin

8. By Application

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
8.3. Market Attractiveness Index, By Application Segment
- 8.3.1. Government Tender*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Market Sales

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. The U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. The U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. The Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Boehringer Ingelheim International GmbH*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Panav Bio-tech
11.3. Ceva
11.4. Bioveta, a.s.
11.5. Indian Immunologicals Limited
11.6. Qilu Animal Health Products Co., Ltd.
11.7. Tianjin Ruipu Biotechnology Co., Ltd.
11.8. Merck & Co., Inc.(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

12.1. Appendix
12.2. About Us and Services
12.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

2022-2029 年全球猪瘟 (CSF) 疫苗市场